Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk Safety is important, but efficacy is essential for drugs. However, in the case of drug-drug interaction (DDI), safety is always considered an important issue to be addressed. With regard to transporter-based DDI, major transporter molecules responsible for clearance of compound from blood circulation, e.g. MDR1, BCRP, MRPs, OATPs, OATs, OCTs and MATE, that are functional in intestinal, hepatic and renal secretion/excretion of drugs are targets and the risk of an increase in plasma concentration of the victim drug is evaluated due to inhibition by perpetrators. However, several studies have reported decreased systemic exposure of orally administered drugs by taking them with a beverage, which causes drug-beverage interaction. In the case of fexofenadine, 1, 2) our study demonstrated that the plasma AUC of fexofenadine is decreased to about 15% of that of the control when coadministered with apple juice. 1) This observation suggests that interaction of drugs with beverages in the gut may lead to a decrease or loss of efficacy of drugs. Although there are several possible mechanisms in drugbeverage interactions on the intestinal absorption process including changes of luminal pH, solubility of drugs, and motility of gut tissues, we are currently studying the possibility of an intestinal uptake transporter that mediates drug absorption.
A predominant role of OATP2B1 expressed in human small intestinal tissues has been described in drug absorption, [3] [4] [5] and postulated as a transporter for a variety of drugs. A contribution of OATP2B1 to in vivo drug absorption has been demonstrated, since a lower plasma concentration of fexofenadine was observed in individuals who carry a genetic variant of the SLCO2B1 gene with a loss-of-function mutation than individuals with the wild-type genotype. 1, 6) Furthermore, it has been also confirmed that fruit juices affect the transport activity of OATP2B1 using in vitro OATP2B1-expressing cultured cells. Accordingly, although further studies to support the hypothesis are required, currently obtained results can be explained by supposing that OATP2B1 is responsible for intestinal absorption of drugs and that its activity is affected by fruit juices. This means that any simultaneously administered drugs could cause DDI on OATP2B1 in a manner similar to those juices.
As the mechanism of interaction of OATP2B1 substrate drugs with fruit juice, especially apple juice, at least two mechanisms are considered, namely, competitive-type inhibition and apparently non-competitive type inhibition. 7, 8) The former is easy to understand in that any components in fruit juice may compete with the drug at the active site on OATP2B1. The latter is a longlasting inhibition shown by the fact that the inhibitory effect continues for a certain time even after a washout of juice from the uptake medium by preincubating the juice with OATP2B1. One of hypothetical mechanisms for a long-lasting effect is that functional OATP2B1 proteins may be reduced from the membrane surface due to activation of protein kinase C by apple juice, since OATP2B1 has been shown to be internalized by protein kinase C activation. 9) In addition, other possibilities such as strong binding of a juice component to OATP2B1 and accumulation of an inhibitory component in the cells are possible. But it is important that even after the removal of juice, OATP2B1 activity could be affected, which means that such a long-lasting effect of juice continues for a while when taking drugs orally in vivo.
Even if it is accepted that OATP2B1 participates in drug absorption, the relative contribution of OATP2B1 remains unclear. There is a criticism that even when drug transport mediated by OATP2B1 is inhibited by juices in in vitro experiments, no significant difference in plasma concentration is observed after consumption with juice in vivo. This discrepancy may be explained partially by the presence of multiple binding sites which differ in affinity to respective substrates/inhibitors for OATP2B1.
10) Distinction in affinity to substrate between those two sites (low-affinity and high-affinity sites) likely contributes to total membrane transport, depending upon the concentration of variable substrate drugs; specifically, the in vivo gut luminal concentration might be higher than that demonstrated by in vitro studies and only the highaffinity site, not the low affinity site, may be affected by juice components. The idea of multiple binding sites is not rare and other transporters such as MDR1 are also known to show such characteristics.
11)
There is interesting discussion in recently published articles on the contribution of transporters to the membrane transport of drugs in comparison with simple diffusion. 12, 13) One asserts that the transporter predominantly contributes to drug transport, while most pharmaceutical scientists including myself believe that simple diffusion and transporters coexist and the contribution of those mechanisms is dependent on drugs, target tissues, and concentration at the site of transport. Although it is generally easier to accept that clearance transporters recognize drugs as substrates, as described in the beginning, it is also true that the number of drugs and even lipophilic endogenous compounds such as cholesterol that have been found to cross the membrane via transporters is increasing in intestinal absorption as well as clearance processes. Thus, we may need to consider more carefully the mechanisms of membrane transport of drugs in the intestinal absorption process in a similar manner as with clearance organs. If an uptake transporter contributes more than we expected before, there may be higher possibility that absorptive transport might be affected by any coadministered drugs or food/beverage. OATP2B1 is just an Drug Metab. Pharmacokinet. 28 (6): 451-452 (2013).
Copyright © 2013 by the Japanese Society for the Study of Xenobiotics (JSSX) example and there might be other drugs that are taken up by other transporters. This concept may not be limited to the intestinal absorption process, and the distribution from blood to target tissues other than clearance organs might be explained by specialized transporters. That is, target-tissue distribution of drugs might be affected by circulating drugs administered simultaneously. Therefore, DDI may lead to a decrease in efficacy of drugs by reducing not only tissue distribution but also intestinal absorption of the victim drugs which may not lead to toxicity. Better appreciation for uptake transporters should facilitate efficacious pharmacotherapy and drug development.
